SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (105)11/29/2006 10:36:37 AM
From: kenhott  Respond to of 285
 
Conversion agents have been approved looking primarily at conversion rates for efficacy. Of course available relapse data would be submitted as part of the NDA package. If the duration is nonsense then it wouldn't pass the efficacy hurdle no matter how high the conversion rate. But given a reasonable expectation of duration, conversion rate is the key.

Orals are for prevention so recurrence is the key endpoint.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News